TreatmentTrends: Multiple Sclerosis (US) is an annual syndicated report that provides a comprehensive view of the current and anticipated management of multiple sclerosis (MS) based on primary research with neurologists. These reports cover the use of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth, and anticipated use. In addition, respondents are queried about their awareness of and interest in DMTs in development.
Questions Answered in This Report:
- What is neurologists’ relative MS patient load by disease classification (CIS, RR-MS, SP-MS, PP-MS)?
- What differences exist in the prescribing of DMTs based upon patient type (e.g., disease classification, line of therapy, etc.)?
- What product attributes are most important to neurologists when they are selecting a specific DMT? How do neurologists perceive the currently marketed agents to perform against each attribute and against each other?
- How is prescribing of each DMT anticipated to change over the next six months? What factors are driving the anticipated trends?
- What sales strategies and messaging efforts are the marketers of the key DMT brands employing?
- What is the current awareness of and interest in DMTs in late-stage clinical development among neurologists?
Sample Frame & Methodology:
~100 US neurologists complete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback.
To qualify, respondents must meet the following criteria:
- Minimum of 20 patients with relapsing-remitting MS (RR-MS) under management
- Have been in practice a minimum of 2 years and a maximum of 35 years
- More than 75% of professional time spent in clinical practice
Key Drugs Covered:
Aubagio (teriflunomide), Avonex (interferon-beta-1a intramuscular), Betaseron (interferon-beta-1b subcutaneous), Copaxone 20 mg (glatiramer acetate), Copaxone 40 mg 3TW (glatiramer acetate), Extavia (interferon-beta-1b subcutaneous), Gilenya (fingolimod), Rebif (interferon -beta-1a subcutaneous), Tecfidera (dimethyl fumarate), Tysabri (natalizumab), Lemtrada (alemtuzumab), Copaxone 40 mg/1 mL, Plegridy (pegylated interferonbeta- 1a subcutaneous), laquinimod, daclizumab, ocrelizumab
Key Companies Mentioned:
AbbVie, Active Biotech, Bayer, Biogen Idec, EMD Serono (a Merck KGaA company), Genentech, Genzyme (a Sanofi company), Novartis, Pfizer, Roche, Teva
- Final report in Powerpoint format
- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request
- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions
- Special Report: How are Novel Follow-On Therapies Impacting Multiple Sclerosis Treatment Paradigms (US) 2014
- TreatmentTrends®: Multiple Sclerosis (EU) 2013
- ChartTrends®: Multiple Sclerosis (US) 2014
- LaunchTrends®: Aubagio (US) 2013
- LaunchTrends®: Tecfidera (US) 2014
- LaunchTrends®: Lemtrada (US) TBD
- DecisionBase®: Multiple Sclerosis-Relapsing Remitting 2014
- DecisionBase®: Multiple Sclerosis-Chronic Progressive 2014
- Pharmacor®: Multiple Sclerosis 2014
- Treatment Algorithms®: Multiple Sclerosis 2014
- Physician and Payer Forum®: Multiple Sclerosis (EU) 2014
- PatientBase®: Multiple Sclerosis in G7 2014